Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
· inc., wave life sciences usa
AI Briefing
- Wave Life Sciences reports positive FDA acceptance of Phase 2a trial for WVE-007
- Trial remains on track to initiate in 2Q 2026
- Phase 2a trial aims to test INHBE GalNAc-siRNA for type 2 diabetes
Advertisement